Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Efficacy and safety of zanubrutinib combined with reduced-dose bendamustine and Rituximab for eldly Mantle Cell Lymphoma: A retrospective analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

CLChuan‐Yuan Li

Discussion

Loading...

Member takes

Overview

Retrospective analysis indicates improved outcomes with Zanubrutinib-augmented treatment for elderly patients with mantle cell lymphoma.

Key Points

  • To evaluate the efficacy and safety of reduced-dose Bendamustine combined with Rituximab and Zanubrutinib for elderly patients with mantle cell lymphoma.
  • Retrospective analysis of 23 elderly patients with mantle cell lymphoma.
  • Treatment involved reduced-dose Bendamustine, Rituximab, and Zanubrutinib across six cycles.
  • Assessment of minimal residual disease using NGS and immunological function after treatment.
  • Complete response rate was 73.9% and overall response rate was 91.3%.
  • Progression-free survival rate at 24 months was 75.4% and overall survival rate was 90.7%.
  • Undetectable MRD rate increased from 88% to 94% after Zanubrutinib maintenance therapy.

Cite This Study

Chuan‐Yuan Li (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d1b5https://doi.org/10.1182/blood-2025-7097
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of zanubrutinib-containing regimens in patients with newly diagnosed Mantle Cell Lymphoma: Interim results from a Phase II investigator-initiated study2025
  2. 2Zanubrutinib maintenance post-autologous stem cell transplantation in Mantle Cell Lymphoma: A prospective multicenter Phase II trial2025
  3. 3Efficacy and safety of zanubrutinib combined with anti-CD20 monoclonal antibody-based regimens as first-line therapy in high-risk follicular lymphoma and marginal zone lymphoma: A single-arm retrospective study2025
  4. 4Zanubrutinib in combination with R-CHOP for previously untreated mcd type of Diffuse large b-cell lymphoma (DLBCL).2025
  5. 5Zanubrutinib combined with bendamustine and rituximab in previously untreated patients with advanced follicular lymphoma: A prospective, open-label, single-arm phase II clinical study2025